Delivery Order SPE2DB22D3301-SPE2DB26FX4KB
Award Date 11/5/25
Potential Completion Date 11/28/25
Potential Value $4.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This $4,252.30 delivery order, which carries a firm fixed price contract type with no set-aside designation, is scheduled for completion by November 12, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. Tecentriq is a specialized pharmaceutical product used in oncology treatment, reflecting the critical role...
- The Defense Logistics Agency awarded a $17,009.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Tecentriq (atezolizumab) 840 mg/14 mL vials on May 19, 2025, with completion targeted for June 10, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, which carries a $999,999,999 ceiling and runs through December 2026. The pharmaceutical distributor is...
- The Defense Logistics Agency awarded a $17,009.24 delivery order to AmerisourceBergen Drug Corp for Tecentriq 840 mg/14 ml vials on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and a major distribution hub for federal pharmaceutical...
- The Defense Logistics Agency awarded a $25,189 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tecentriq Hybridza 1,875 mg 15 ml pharmaceutical product. This is a non-set-aside competitive award with an ultimate completion date of September 30, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Tecentriq 840 mg/14 ml vials. The contract is valued at $17,009.24 under a firm fixed-price arrangement with an ultimate completion date of May 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $6,297.24 delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Tecentriq Hybreza 1,875 mg in 15 ml quantities. This contract represents a firm fixed-price delivery order with an ultimate completion date of May 13, 2025, and carries no set-aside designation, indicating it was awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $34,018.40 contract is for the supply of 840 mg/14 ml vials of the cancer medication Tecentriq. The delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical to provide a wide range of pharmaceutical products and medical supplies in support of military...
- The Defense Logistics Agency awarded a $7,857.18 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 840 mg/14 ml vials of Tecentriq, a cancer immunotherapy drug. To be performed in Conshohocken, Pennsylvania from June 20 through July 12, 2023, this order was issued against an existing DLA pharmaceutical supply contract vehicle. As a top defense agency procuring all manner of supplies for the military, DLA aims to ensure troops have needed medicines while supporting medical...
- The Defense Logistics Agency awarded a $8,243.54 delivery order to AmerisourceBergen Drug Corp for 4,569,930,973 units of Actemra 400 mg/20 ml vials. This is a non-set-aside, competitively awarded firm fixed-price delivery order with a completion date of November 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency valued at $4,894.92 for Actemra 162 mg/0.9 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of June 18, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...